Related Experiment Video
Updated: Jul 11, 2026

08:49
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined
Chien-Hsing Chang1, Edmund A Rossi, David M Goldenberg
1Immunomedics, Inc., Morris Plains, NJ 07950, USA. kchang@immunomedics.com
Summary
The dock and lock (DNL) method creates complex bioactive molecules using specific protein domains. This approach enables the development of novel therapeutics and improved recombinant products like vaccines and antibodies.
Area of Science:
- Biotechnology
- Protein Engineering
- Molecular Biology
Background:
- The dock and lock (DNL) method leverages natural protein interactions for molecular assembly.
- It utilizes specific domains from protein kinase A (PKA) and A-kinase anchoring proteins.
Purpose of the Study:
- To review the concept, approach, and proof-of-concept of the DNL method.
- To highlight its potential for creating multivalent and multifunctional bioactive molecules.
- To demonstrate its application in generating novel therapeutics and recombinant products.
Main Methods:
- The DNL method involves attaching distinct protein domains (PKA's dimerization/docking domain and A-kinase anchoring protein's anchoring domain) to biological entities.
- These modified entities form stable, well-defined complexes upon combination.
- Genetic engineering and conjugation chemistry are integrated for precise molecular construction.
Main Results:
- The DNL method was validated by creating trivalent bispecific binding proteins.
- These proteins consisted of site-specifically linked Fab fragments, demonstrating controlled assembly.
- The method ensures that individual component functions are retained within the complex.
Conclusions:
- The DNL method offers a powerful strategy for designing complex bioactive molecules.
- It holds significant potential for developing innovative human therapeutics.
- The DNL approach promises advancements in recombinant products such as cytokines, vaccines, and monoclonal antibodies.

